Does Glucagon Inhibit Insulin? Research Data Analysis
Abstract: Glucagon does not directly inhibit insulin secretion; rather, it stimulates hepatic glucose output, creating a counter-regulatory feedback loop. Research data from 2023–2024 indicates glucagon’s role in glucose homeostasis, with clinical studies showing no direct suppression of β-cell insulin release. In the peptide product market, glucagon analogs (e.g., dasiglucagon) demonstrate superior stability and rapid onset versus native glucagon. Brand comparisons reveal Novo Nordisk’s Zegalogue® leads in regulatory approvals (FDA/EMA), while generic peptides lag in purity (≥98% vs. ≥95%). Key technical advantages include enhanced half-life (2–4 hours) and reduced immunogenicity. Market trends project 8.5% CAGR (2024–2030), driven by diabetes and hypoglycemia management. Product selection prioritizes GMP-certified facilities, third-party purity assays, and cold-chain logistics (2–8°C). Industry challenges include high production costs and variable bioactivity across suppliers.